文献速递甲状腺疾病

全球甲状腺癌流行病学格局:GLOBOCAN 2020年发病率和死亡率估计

The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-03-07

该研究从GLOBOCAN数据库提取185个国家或地区2020年甲状腺癌年龄标化发病率和死亡率,按性别和18个年龄组分析。全球女性发病率为10.1/10万、男性为3.1/10万,女性死亡率为0.5/10万、男性为0.3/10万。高和极高人类发展指数国家发病率是低和中人类发展指数国家的5倍,而死亡率在不同地区相对相似。

要点

  • 2020年全球甲状腺癌年龄标化发病率女性10.1/10万、男性3.1/10万。
  • 高和极高人类发展指数国家发病率是低和中人类发展指数国家的5倍。
  • 女性发病率在世界各地区间相差超过15倍。

核心结论

  • 当前甲状腺癌流行病学格局强烈提示全球许多国家和地区的过度诊断效应显著,证实甲状腺癌过度诊断是全球公共卫生问题。

研究设计与样本

  • 从GLOBOCAN数据库提取185个国家或地区2020年甲状腺癌年龄标化发病率和死亡率,按性别和18个年龄组分析。
  • 发病率和死亡率按国家和联合国定义的20个世界区域及四级人类发展指数汇总。

主要发现

  • 2020年全球甲状腺癌年龄标化发病率女性为10.1/10万、男性为3.1/10万。
  • 2020年全球甲状腺癌年龄标化死亡率女性为0.5/10万、男性为0.3/10万。
  • 两性中,高和极高人类发展指数国家发病率是低和中人类发展指数国家的5倍,而死亡率在不同地区相对相似。
  • 女性发病率在世界各地区间相差超过15倍,最高在密克罗尼西亚联邦和法属波利尼西亚(18.5/10万女性)、北美(18.4/10万)和东亚(17.8/10万,其中韩国达45/10万)。
  • 大多数国家两性死亡率均低于1/10万,韩国两性发病率与死亡率比值最高,其次为塞浦路斯和加拿大。

关键数值与推荐

  • 甲状腺癌定义采用国际肿瘤疾病分类第10版编码C73。
  • 发病率与死亡率均以每10万人年年龄标化率表示。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid cancer incidence rates have increased in many countries and settings; however, mortality rates have remained stable at lower rates. This epidemiological pattern has been largely attributed to an overdiagnosis effect. Timely evidence for the global epidemiological status is necessary to identify the magnitude of this problem and the areas mostly affected by it. We therefore aimed to provide an up-to-date assessment on the global distribution of thyroid cancer incidence and mortality rates in 2020. METHODS: We extracted age-standardised incidence and mortality rates per 100 000 person-years of thyroid cancer as defined by the International Classification of Diseases for Oncology 10th Revision (code C73), for 185 countries or territories by sex and 18 age groups (ie, 0-4, 5-9, …, 80-84, and ≥85 years) from the GLOBOCAN database. Both incidence and mortality estimates were presented by country and aggregated across the 20 UN-defined world regions and according to the UN's four-tier Human Development Index (ie, low, medium, high, and very high) in 2020. FINDINGS: Globally, in 2020, the age-standardised incidence rates of thyroid cancer were 10·1 per 100 000 women and 3·1 per 100 000 men, and age-standardised mortality rates were 0·5 per 100 000 women and 0·3 per 100 000 men. In both sexes, incidence rates were five times higher in high and very high Human Development Index countries than in low and medium Human Development Index countries, whereas mortality rates were relatively similar across different settings. Incidence rates in women differed by more than 15 times across world regions, with the highest incidence rates being in the Federated States of Micronesia and French Polynesia (18·5 per 100 000 women), North America (18·4 per 100 000), and east Asia (17·8 per 100 000, with South Korea reaching 45 per 100 000). Mortality rates were less than one per 100 000 in most countries and in both sexes. South Korea had the highest incidence-to-mortality rate ratio in both sexes, followed by Cyprus and Canada. INTERPRETATION: The current thyroid cancer epidemiological landscape is strongly suggestive of a large effect of overdiagnosis in many countries and settings worldwide, confirming the relevance of thyroid cancer overdiagnosis as a global public health problem. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022. PMID: 35271818. doi:10.1016/S2213-8587(22)00035-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。